AbbVie (ABBV)
(Delayed Data from NYSE)
$155.34 USD
-1.72 (-1.10%)
Updated May 28, 2024 04:00 PM ET
After-Market: $155.00 -0.34 (-0.22%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum C VGM
Brokerage Reports
0 items in cart
AbbVie Inc. [ABBV]
Reports for Purchase
Showing records 241 - 260 ( 378 total )
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Biotechnology: Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended January 17 2020
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Hem. Malignancies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Humira continues to face stiff competition from biosimilars in Europe
Provider: Arrowhead Business and Investment Decisions
Analyst: Research Department
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
We have revised our revenue estimates for Humira downwards based on AbbVie?s latest guidance